This is an early clinical milestone with no efficacy data — the stock may see modest positive drift from de-risking, but the next meaningful catalyst is the interim readout in H2 2027. Monitor enrollment updates and any safety signals from the SAD portion.
Price Chart
Executive Summary
Korro Bio dosed the first cohort of healthy volunteers in its Phase 1/2 ANCHOR trial for KRRO-121, a GalNAc-conjugated RNA-editing oligonucleotide for hyperammonemia in urea cycle disorders (UCDs) and hepatic encephalopathy (HE). The trial is in early stages with UCD patient dosing expected in H1 2027 and an interim readout in H2 2027 — no efficacy data yet, but the milestone de-risks the program's clinical execution.
Key Facts
- First cohort of healthy volunteers dosed in Phase 1/2 ANCHOR trial for KRRO-121 (GalNAc-conjugated REO targeting hyperammonemia in UCDs and HE).
- Trial design: Part 1 (SAD/MAD in up to 50 healthy volunteers) and Part 2 (Phase 2 in up to 15 UCD patients).
- UCD patient dosing expected H1 2027; interim clinical readout expected H2 2027.
- KRRO-121 designed as a pan-UCD treatment via synthetic rescue of glutamine synthetase, with potential for infrequent subcutaneous dosing.
Financial Impact
No financial data disclosed; early clinical milestone with no revenue or cost figures.
Risk Factors
- Clinical trial failure (safety or efficacy) could lead to significant downside.
- Long timeline to data (H2 2027) with no near-term catalysts.
- Competition from existing UCD therapies (nitrogen scavengers, diet) and other RNA-editing approaches.
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3374998 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 today | Insider Buy | $12.46 | awaiting T+1 | — | $12.02 (−3.53%) |
Oct 22, 2026 4d ago | 8-K | $12.05 $11.98 | ▼ −0.58% | ▼ −0.06% | $12.02 (−0.25%) |
Oct 16, 2026 10d ago | Press Release | $8.91 $9.44 | ▲ +5.95% | ▲ +5.61% | $12.02 (+34.90%) |
Oct 5, 2026 21d ago | 8-K | $9.76 $10.49 | ▲ +7.48% | ▲ +7.72% | $12.02 (+23.16%) |
Oct 5, 2026 21d ago | Press Release | $9.76 $10.49 | ▲ +7.48% | ▲ +7.72% | $12.02 (+23.16%) |
Sep 15, 2026 5w ago | Insider Cluster | $13.83 $11.80 | ▼ −14.68% | ▼ −15.81% | $12.02 (−13.09%) |
Aug 13, 2026 10w ago | Insider Cluster | $13.29 $13.28 | ▼ −0.08% | ▲ +0.12% | $12.02 (−9.56%) |
Aug 6, 2026 11w ago | 8-K | $12.12 $13.25 | ▲ +9.32% | ▲ +8.71% | $12.02 (−0.83%) |
Jul 9, 2026 15w ago | Institutional Cluster | $14.30 $14.56 | ▲ +1.82% | ▲ +1.39% | $12.02 (−15.94%) |
Jun 24, 2026 17w ago | Insider Cluster | $12.17 $12.70 | ▼ −4.36% | ▼ −5.08% | $12.02 (+1.23%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers